Skip to main content

melanoma Archives

Melanoma response to immune therapy

Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

Read more


Combining treatments for melanoma

Feb. 18, 2016—Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.

Read more


Investigators find clues to melanoma treatment resistance

Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

Read more


Gene mutations may predict melanoma response to immunotherapies

Mar. 12, 2015—Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

Read more


Study tracks combination therapy to treat melanoma

Jan. 8, 2015—Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.

Read more


Immune cell activity and melanoma

Nov. 6, 2014—The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.

Read more


Indiana couple hits the links to support melanoma research

Oct. 16, 2014—A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.

Read more


VICC researchers in spotlight at national cancer conference

Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

Read more


VU study identifies new gene fusions in melanoma

Dec. 19, 2013—Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.

Read more


Foundation lauds graduate student’s melanoma research

Mar. 28, 2013—Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation.

Read more


Combined drug therapy may delay melanoma progression

Oct. 25, 2012—Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.

Read more


Study finds mutation in melanoma sensitive to drug

Jul. 26, 2012—An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more